

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE

05 FEB 14 AM 10:12
LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name	
Organization	Novo Nordisk Pharmaceuticals, Inc.
2. Address ☐ Check if different than previously reported	
Address 1	2401 Pennsylvania Ave., NW, Ste. # 300
City	Washington
State	DC
Zip Code	20037
Country	US
3. Principal place of business (if different than line 2)	
City	Princeton
State	NJ
Zip Code	08540
Country	US
4a. Contact Name	b. Telephone number
Prefix Full Name	c. E-mail
Mr. Michael Mawby	202-663-7851 mmby@novonordisk.com
7. Client Name ☒ Self	5. Senate ID #
Novo Nordisk Pharmaceuticals, Inc.	284790-
	6. House ID #
	3690301

TYPE OF REPORT 8. Year 2004 Midyear (January 1-June 30) ☐ OR Year End (July 1-December 31) ☐

9. Check if this filing amends a previously filed version of this report ☐10. Check if this is a Termination Report ☐ ⇒ Termination Date 02/10/200511. No Lobbying Act ☐**INCOME OR EXPENSES - Complete Either Line 12 OR Line 13**

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000 ☐\$10,000 or more ☐ ⇒ \$ _

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this report were:

Less than \$10,000 ☐\$10,000 or more ☒ ⇒ \$ _ 40,000

14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of

- ☒ Method A. Reporting amounts using LDA definition
- ☐ Method B. Reporting amounts under section 6033(c) Internal Revenue Code
- ☐ Method C. Reporting amounts under section 162(e) Revenue Code

Form

Printed Name and Title Michael Mawby, Chief Government Affairs Officer

Registrant Name Novo Nordisk Pharmaceuticals, Inc. Client Name Novo Nordisk Pharmaceuticals, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code BUD - Budget/Appropriations (one per page)

16. Specific lobbying issues

Add page to continue specific issues description for this issue

FY 2005 Appropriations for HHS diabetes related activities including funding for National Diabetes Education Program

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

Senate
House
HHS
CDC, NIDDK

18. Name of each individual who acted as a lobbyist in this issue area Add a page to continue adding lobbyists to

Name			Covered Official Position (if applicable)
First Name	Last Name	Suffix	
Michael	Mawby		Chief Government Affairs Officer
Steve	McGill		Associate Director, Government Affairs
Peter	Norman		Senior Manager, Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Add a page for a d

Printed Name and Title Michael Mawby, Chief Government Affairs Officer

LD-2DS (REV. 4/03)

Page _

Registrant Name Novo Nordisk Pharmaceuticals, Inc.Client Name Novo Nordisk Pharmaceuticals, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each cod** information as requested. Attach additional page(s) as needed.

15. General issue area code CPT - Copyright/Patent/Trademark (one per page)

16. Specific lobbying issues

Add page to continue specific issues description for this issue 

H.R. 1561, the United States Patent and Trademark Fee Modernization Act of 2003; related patent, trademark and intellectual property issues.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

Senate
House
Commerce
PTO

18. Name of each individual who acted as a lobbyist in this issue area Add a page to continue adding lobbyists for

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Michael	Mawby		Chief Government Affairs Officer
Steve	McGill		Associate Director, Government Affairs
Peter	Norman		Senior Manager, Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Add a page for a d

Printed Name and Title Michael Mawby, Chief Government Affairs Officer

LD-2DS (REV. 4/03)

Page _

Registrant Name Novo Nordisk Pharmaceuticals, Inc.Client Name Novo Nordisk Pharmaceuticals, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each cod** information as requested. Attach additional page(s) as needed.

15. General issue area code HCR - Health Issues (one per page)

16. Specific lobbying issues

Add page to continue specific issues description for this issue

S.1666, Diabetes Prevention and Treatment Act of 2003; all sections.

HR 1916, Diabetes Prevention Access and Care Act; all sections.

HR 3194, Diabetes Self-Management Training Act of 2003; all sections.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

Senate
House
HHS, CMS, CDC, NIDDK

18. Name of each individual who acted as a lobbyist in this issue area Add a page to continue adding lobbyists for

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Michael	Mawby		Chief Government Affairs Officer
Steve	McGill		Associate Director, Government Affairs
Peter	Norman		Senior Manager, Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Add a page for a d

Printed Name and Title Michael Mawby, Chief Government Affairs Officer

LD-2DS (REV. 4/03)

Page

Client Name Novo Nordisk Pharmaceuticals, Inc.

15. General issue area code MMM - Medicare/Medicaid (one per page)

Add page to continue specific issues description for this issue

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

Senate
House
HHS, CMS, CDC, NIDDK

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists to*

[illegible]

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Printed Name and Title Michael Mawby, Chief Government Affairs Officer

LD-2DS (REV. 4/03)

Page .

Registrant Name Novo Nordisk Pharmaceuticals, Inc. Client Name Novo Nordisk Pharmaceuticals, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code TAX - Taxation/Internal Revenue Code (one per page)

16. Specific lobbying issues

Add page to continue specific issues description for this issue 

strengthen support for passage of the R&D tax credit,

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

Senate
House

18. Name of each individual who acted as a lobbyist in this issue area Add a page to continue adding lobbyists to

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Michael	Mawby		Chief Government Affairs Officer
Steve	McGill		Associate Director, Government Affairs
Peter	Norman		Senior Manager, Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Add a page for a

Printed Name and Title Michael Mawby, Chief Government Affairs Officer

LD-2DS (REV. 4/03)

Page

Registrant Name Novo Nordisk Pharmaceuticals, Inc. Client Name Novo Nordisk Pharmaceuticals, Inc.

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address

City

State

Zip Code

Country

21. Client new principal place of business (if different than line 20)

City

State

Zip Code

Country

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

First Name

Last Name

Suffix

First Name

Last Name

Su

1

3

2

4

ISSUE UPDATE

Find the code to select below.

24. General lobbying issues that **no longer** pertain

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal place of Business (city and state or country)
	Address	City
	C/S/Z	State Country
	Address	City
	C/S/Z	State

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

1

2

3

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Street Address City	Address State/Province Country	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Overseas personnel
			City		
			State Country		

28. Name of each previously reported foreign entity that **no longer** owns, **or** controls, **or** is affiliated with the registrant affiliated organization

1

3

5

2

4

6

Add a page for more

Printed Name and Title Michael Mawby, Chief Government Affairs Officer

LD-2DS (REV. 4/03)

Page